8-K: Genprex Expands Lung Cancer Gene Therapy Trials

Genprex, Inc. announced the addition of a new clinical trial site and plans for further expansion for its lead drug candidate, Reqorsa Gene Therapy, in lung cancer studies.

Summary

• Genprex, Inc. has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for its Acclaim-1 and Acclaim-3 clinical trials.
• The company plans to open additional clinical trial sites in the coming months to expand patient reach and expedite enrollment.
• Acclaim-1 is a Phase 1/2 trial evaluating REQORSA in combination with AstraZeneca's Tagrisso for late-stage non-small cell lung cancer (NSCLC) patients with activating EGFR mutations who have experienced disease progression after Tagrisso treatment.
• The Phase 1 dose escalation portion of Acclaim-1 showed REQORSA was generally well tolerated with no dose-limiting toxicities and early signs of efficacy, including prolonged progression-free survival and one patient achieving a partial response.
• The Phase 2a expansion portion of Acclaim-1 is expected to enroll approximately 33 patients, with an interim analysis planned after 19 patients are treated, anticipated in the first half of 2026.
• Acclaim-3 is a Phase 1/2 trial evaluating REQORSA in combination with Genentech's Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates for maintenance therapy after initial standard of care treatment.
• The Phase 1 dose escalation portion of Acclaim-3 also showed REQORSA was generally well tolerated with no dose-limiting toxicities.
• The Phase 2 expansion portion of Acclaim-3 is expected to enroll approximately 50 patients, with an interim analysis planned after the 25th patient enrolled and treated reaches 18 weeks of follow-up, anticipated in the first half of 2026.
• Both Acclaim-1 and Acclaim-3 clinical trials have received U.S. Food and Drug Administration (FDA) Fast Track Designation, and Acclaim-3 also holds Orphan Drug Designation.

Sentiment

Score: 7

Explanation: The announcement is positive, detailing progress in clinical trials, expansion of sites, and reiterating positive Phase 1 results and regulatory designations. However, it's an operational update rather than a definitive clinical success announcement, and the inherent risks of clinical development remain.

Positives

• Addition of Gabrail Cancer Center as a new clinical trial site for Acclaim-1 and Acclaim-3 trials.
• Plans to add and open additional clinical trial sites over the coming months to expand patient reach and expedite enrollment.
• Successful completion of the Phase 1 dose escalation portion of Acclaim-1, demonstrating REQORSA was generally well tolerated with no dose-limiting toxicities.
• Early signs of efficacy observed in Acclaim-1 Phase 1, including prolonged progression-free survival and one patient achieving a partial response.
• Successful completion of the Phase 1 dose escalation portion of Acclaim-3, showing REQORSA was generally well tolerated with no dose-limiting toxicities.
• Acclaim-1 clinical trial has received U.S. FDA Fast Track Designation.
• Acclaim-3 clinical trial has received U.S. FDA Fast Track Designation and Orphan Drug Designation.

Risks

• Ability to advance the clinical development, manufacturing, and commercialization of product candidates in accordance with projected timelines and specifications, including the adding and opening of additional clinical trial sites.
• Timing and success of clinical trials and regulatory approvals.
• The effect of product candidates, alone and in combination with other therapies, on cancer and diabetes.
• The effects of any strategic research and development prioritization initiatives, and the extent to which such efforts can be implemented successfully to achieve desired results.
• Future growth and financial status, including the ability to maintain compliance with Nasdaq listing requirements, continue as a going concern, and obtain capital to meet long-term liquidity needs on acceptable terms, or at all.
• Commercial and strategic partnerships, including those with third-party vendors, suppliers, and manufacturers, and their ability to successfully perform and scale up the manufacture of product candidates.
• Intellectual property and licenses.
• Actual results may differ materially from forward-looking statements due to various important factors and uncertainties.

Future Outlook

Genprex expects to add and open additional clinical trial sites for its Acclaim clinical trials over the coming months to expand patient reach and expedite enrollment. The company anticipates completing enrollment of the first 19 patients for interim analysis in the Acclaim-1 Phase 2a expansion study in the first half of 2026. Similarly, Genprex expects to complete enrollment of the first 25 patients for interim analysis in the Acclaim-3 Phase 2 expansion study in the first half of 2026.

Management Comments

• "The Company expects to add and open additional clinical trial sites for its Acclaim clinical trials over the coming months in an effort to expand its reach to additional patients and expedite enrollment."
• "Genprex's team plans to conduct an interim analysis following the treatment of 19 patients, which the Company currently expects to complete enrollment of the first 19 patients in the first half of 2026."
• "Genprex's team plans to conduct an interim analysis after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026."

Industry Context

This announcement highlights Genprex's continued advancement in the competitive lung cancer treatment landscape, particularly in gene therapy. The focus on non-small cell lung cancer (NSCLC) with EGFR mutations and extensive stage small cell lung cancer (ES-SCLC) addresses significant unmet medical needs. Combining REQORSA with established therapies like AstraZeneca's Tagrisso and Genentech's Tecentriq reflects a common strategy in oncology to enhance efficacy and overcome resistance, aligning with broader industry trends towards combination therapies and personalized medicine. The FDA Fast Track and Orphan Drug designations underscore the potential significance of REQORSA in these indications.

Stakeholder Impact

• Shareholders: Potential positive impact due to clinical trial progress and expansion, which could de-risk the drug development process and increase the likelihood of future success. However, the 'going concern' risk and need for capital are noted.
• Patients: Increased access to investigational therapies through new clinical trial sites.
• Employees: Continued work on advancing key drug candidates.
• Partners (AstraZeneca, Genentech): Continued collaboration on combination therapies.
• Regulatory Authorities (FDA): Ongoing oversight of Fast Track and Orphan Drug designated trials.

Next Steps

• Add and open additional clinical trial sites for Acclaim clinical trials over the coming months.
• Enroll approximately 33 patients in the Acclaim-1 Phase 2a expansion study.
• Conduct an interim analysis for Acclaim-1 after 19 patients are treated.
• Complete enrollment of the first 19 patients for Acclaim-1 interim analysis in the first half of 2026.
• Enroll approximately 50 patients in the Acclaim-3 Phase 2 expansion study.
• Conduct an interim analysis for Acclaim-3 after the 25th patient enrolled and treated reaches 18 weeks of follow up.
• Complete enrollment of the first 25 patients for Acclaim-3 interim analysis in the first half of 2026.

Key Dates

Recommendation

The announcement provides positive operational updates regarding clinical trial expansion and reiterates promising early-stage results and regulatory designations. This progress is crucial for a biotechnology company and helps de-risk the development pathway. However, these are still early to mid-stage trials, and significant clinical and financial risks remain, including the need for future capital and the uncertainty of trial outcomes. While the news is favorable, it does not fundamentally alter the long-term risk/reward profile enough to warrant a 'buy' or 'sell' recommendation at this stage, suggesting a 'hold' for investors awaiting more definitive efficacy data and clarity on financial stability.

Keywords

Genprex, GNPX, Reqorsa Gene Therapy, quaratusugene ozeplasmid, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Clinical Trials, Acclaim-1, Acclaim-3, FDA Fast Track Designation, Orphan Drug Designation, Oncology, Biotechnology, Gene Therapy, AstraZeneca, Tagrisso, osimertinib, Genentech, Tecentriq, atezolizumab